热门资讯> 正文
箭头制药宣布与第六街合作5亿美元战略融资
2024-08-09 04:24
- Arrowhead Pharmaceuticals (NASDAQ:ARWR) on Thursday said it has entered into a strategic financing agreement with Sixth Street for significant, long-term, non-dilutive capital to fund innovation and growth opportunities across Arrowhead’s robust and diverse pipeline of RNAi therapeutics.
- The $500 million senior secured credit facility includes $400 million funded at close with an additional $100 million available at Arrowhead’s option.
- The credit facility matures on August 7, 2031, and bears interest at an annual rate of 15%.
- ARWR -2.12% after hours to $25.3.
- Source: Press Release
More on Arrowhead Pharmaceuticals
- Arrowhead Pharmaceuticals: Driving To Commercialization
- Arrowhead Pharmaceuticals: Hoping Something Sticks
- Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point
- Arrowhead Pharmaceuticals Q3 2024 Earnings Preview
- Goldman starts Arrowhead at neutral, cites RNAi portfolio validation
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
